IDH1 and Myelodysplasia: Our data also supported the preleukemic nature of IDH1/2 mutations, but the persistence of IDH1/2 mutations (VAF>2.5%) in complete remission was associated with adverse outcome, higher chance of relapse or the development of myelodysplasia [19, 44].